M&A Deal Summary |
|
|---|---|
| Date | 2013-10-09 |
| Target | Sherrington Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Sorrento Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 502 |
| Revenue | 40M USD (2020) |
Sorrento Therapeutics is an oncology company that is involved in the development of small molecules, mono- and bi-specific antibodies and antibody drug conjugates for treatment of cancer and associated pain. Sorrento Therapeutics was founded in 2006 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 9 |
| Sector (Life Science) | 2 of 9 |
| Type (Add-on Acquisition) | 2 of 7 |
| State (New York) | 1 of 1 |
| Country (United States) | 2 of 8 |
| Year (2013) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-03-01 |
IgDraSol
Fountain Valley, California, United States IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-05-15 |
IgDraSol
Fountain Valley, California, United States IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers. |
Sell | - |
